Reported Earnings • Feb 08
Third quarter 2026 earnings released: EPS: ₹33.34 (vs ₹28.59 in 3Q 2025) Third quarter 2026 results: EPS: ₹33.34 (up from ₹28.59 in 3Q 2025). Revenue: ₹4.89b (up 11% from 3Q 2025). Net income: ₹451.7m (up 31% from 3Q 2025). Profit margin: 9.2% (up from 7.9% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Feb 02
Kingfa Science & Technology (India) Limited to Report Q3, 2026 Results on Feb 07, 2026 Kingfa Science & Technology (India) Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Feb 07, 2026 Buy Or Sell Opportunity • Jan 29
Now 20% overvalued Over the last 90 days, the stock has fallen 9.1% to ₹4,225. The fair value is estimated to be ₹3,515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 30%. Buy Or Sell Opportunity • Dec 22
Now 20% overvalued Over the last 90 days, the stock has fallen 2.3% to ₹4,284. The fair value is estimated to be ₹3,567, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 30%. Buy Or Sell Opportunity • Nov 27
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 5.0% to ₹4,382. The fair value is estimated to be ₹3,589, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 30%. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹30.36 (vs ₹30.76 in 2Q 2025) Second quarter 2026 results: EPS: ₹30.36. Revenue: ₹4.68b (up 12% from 2Q 2025). Net income: ₹411.4m (up 10% from 2Q 2025). Profit margin: 8.8% (down from 8.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Tillkännagivande • Nov 07
Kingfa Science & Technology (India) Limited to Report Q2, 2026 Results on Nov 12, 2025 Kingfa Science & Technology (India) Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Tillkännagivande • Sep 30
Kingfa Science & Technology (India) Limited Approves Appointment of Subramanyan S. K. as A Non-Executive Independent Director Kingfa Science & Technology (India) Limited announced that at the AGM held on September 29, 2025, approved appointment of Mr. Subramanyan S. K. (DIN:00024614) as a Non-Executive Independent Director. Tillkännagivande • Sep 25
Kingfa Science & Technology (India) Limited announced that it has received INR 4.9999924 billion in funding from Sanshi Fund - I, Custody Bank of Japan, Ltd. RE: RB Amundi Small Cap Equity Mother Fund, SBI Optimal Equity Fund - Long Term, SBI Funds Management Limited On September 24, 2025, Kingfa Science & Technology (India) Limited closed the transaction. The company issued 1,440,920 equity shares at an issue price of INR 3,470 for gross proceeds of INR 4,999,992,400. The transaction includes participation from new investors, Sanshi Fund - I for 72,046 shares and will acquire 0.53% stake, SBI Mutual Fund - SBI Flexicap Fund, a fund managed by SBI Funds Management Limited for 345,821 shares and will acquire 2.55% stake, SBI Funds Management Limited - SBI Automotive Opportunities Fund, a fund managed by SBI Funds Management Limited for 184,438 shares and will acquire 1.36% stake, SBI Conservative Hybrid Fund, a fund managed by SBI Funds Management Limited for 357,348 shares and will acquire 2.64% stake, Custody Bank of Japan, Ltd. RE: RB Amundi Small Cap Equity Mother Fund for 273,775 shares and will acquire 2.02% stake, SBI Optimal Equity Fund - Long Term for 100,864 shares and will acquire 0.74% stake and Sbi Emergent India Fund, a fund managed by SBI Funds Management Limited for 106,628 shares and will acquire 0.79% stake. The transaction has been approved by the board of directors. New Risk • Sep 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • Aug 25
Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 29, 2025 Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 29, 2025, at 11:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹4,145, the stock trades at a trailing P/E ratio of 32.7x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 328% over the past three years. Reported Earnings • Jul 31
First quarter 2026 earnings released: EPS: ₹32.86 (vs ₹32.27 in 1Q 2025) First quarter 2026 results: EPS: ₹32.86 (up from ₹32.27 in 1Q 2025). Revenue: ₹4.66b (up 12% from 1Q 2025). Net income: ₹397.9m (up 1.8% from 1Q 2025). Profit margin: 8.5% (down from 9.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 23
Kingfa Science & Technology (India) Limited to Report Q1, 2026 Results on Jul 30, 2025 Kingfa Science & Technology (India) Limited announced that they will report Q1, 2026 results on Jul 30, 2025 Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹126 (vs ₹101 in FY 2024) Full year 2025 results: EPS: ₹126 (up from ₹101 in FY 2024). Revenue: ₹17.5b (up 18% from FY 2024). Net income: ₹1.53b (up 25% from FY 2024). Profit margin: 8.7% (up from 8.2% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 52% per year. Tillkännagivande • May 20
Kingfa Science & Technology (India) Limited to Report Q4, 2025 Results on May 28, 2025 Kingfa Science & Technology (India) Limited announced that they will report Q4, 2025 results on May 28, 2025 Tillkännagivande • Apr 01
Kingfa Science & Technology (India) Limited Announces Resignation of Nirnoy Sur as Company Secretary & Compliance Officer, Effective March 31, 2025 Kingfa Science & Technology (India) Limited informed that Mr. Nirnoy Sur has resigned as Company Secretary & Compliance Officer of the Company with effect from March 31,2025. Mr. Nirnoy Sur has tendered his resignation from the position of Company Secretary (Key Managerial Personnel), Compliance Officer and Nodal Officer of the Company vide letter dated February 11, 2025, due to his personal reasons and to pursue professional growth opportunities. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹28.59 (vs ₹20.09 in 3Q 2024) Third quarter 2025 results: EPS: ₹28.59 (up from ₹20.09 in 3Q 2024). Revenue: ₹4.40b (up 12% from 3Q 2024). Net income: ₹346.3m (up 42% from 3Q 2024). Profit margin: 7.9% (up from 6.2% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Feb 11
Kingfa Science & Technology (India) Limited Announces Resignation of Nirnoy Sur as Company Secretary, Effective March 31, 2025 Kingfa Science & Technology (India) Limited approved Resignation of Mr. Nirnoy Sur as Company Secretary & Compliance Officer of the Company. Reason for Change: Resignation, due to his personal reasons and to pursue professional growth opportunities. Date of Cessation: March 31, 2025. Resignation letter date: February 11, 2025. Tillkännagivande • Feb 03
Kingfa Science & Technology (India) Limited to Report Q3, 2025 Results on Feb 11, 2025 Kingfa Science & Technology (India) Limited announced that they will report Q3, 2025 results on Feb 11, 2025 Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹3,363, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 265% over the past three years. Reported Earnings • Oct 30
Second quarter 2025 earnings released: EPS: ₹30.76 (vs ₹24.44 in 2Q 2024) Second quarter 2025 results: EPS: ₹30.76 (up from ₹24.44 in 2Q 2024). Revenue: ₹4.19b (up 20% from 2Q 2024). Net income: ₹372.6m (up 26% from 2Q 2024). Profit margin: 8.9% (up from 8.4% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 47% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Oct 21
Kingfa Science & Technology (India) Limited to Report Q2, 2025 Results on Oct 29, 2024 Kingfa Science & Technology (India) Limited announced that they will report Q2, 2025 results on Oct 29, 2024 Tillkännagivande • Sep 26
Kingfa Science & Technology (India) Limited Approves Dividend for the Financial Year Ended March 31, 2024 Kingfa Science & Technology (India) Limited at its AGM held on 25 September 2024 approved, Declaration of Dividend of INR 10/- per Equity Share of the face value of INR 10/- each (100%), of the Company for the financial year ended March 31, 2024. Upcoming Dividend • Sep 11
Upcoming dividend of ₹10.00 per share Eligible shareholders must have bought the stock before 18 September 2024. Payment date: 24 October 2024. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Tillkännagivande • Aug 29
Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 25, 2024 Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 25, 2024, at 11:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 20
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to ₹3,573, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years. Tillkännagivande • Aug 09
Kingfa Science & Technology (India) Limited Approves the Appointment of Mr. Ramachandran Sudhinder as an Independent Director Kingfa Science & Technology (India) Limited approved the appointment of Mr. Ramachandran Sudhinder (DIN: 10628111) as an Independent Director. Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: ₹32.26 (vs ₹28.93 in 1Q 2024) First quarter 2025 results: EPS: ₹32.26 (up from ₹28.93 in 1Q 2024). Revenue: ₹4.18b (up 24% from 1Q 2024). Net income: ₹390.7m (up 12% from 1Q 2024). Profit margin: 9.3% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 29
Kingfa Science & Technology (India) Limited to Report Q1, 2025 Results on Aug 07, 2024 Kingfa Science & Technology (India) Limited announced that they will report Q1, 2025 results on Aug 07, 2024 New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.9% average weekly change). Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹2,605, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 121% over the past three years. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2,202, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 122% over the past three years. New Risk • Jun 04
New minor risk - Dividend sustainability The company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 0.5% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risk Short dividend paying track record (less than a year of continuous dividend payments). Tillkännagivande • May 30
Kingfa Science & Technology (India) Limited Recommends Dividend for the Financial Year 2023-24 Kingfa Science & Technology (India) Limited recommended a final dividend of 100% i.e., INR 10/- (Rupees Ten Only) per equity share of Face Value of INR 10/- each, for the financial year 2023-24. The final dividend, if approved, by Shareholders in the upcoming AGM, will be paid/dispatched to the eligible shareholders on or before 30th day from the date of 40th Annual General Meeting. Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹101 (vs ₹67.22 in FY 2023) Full year 2024 results: EPS: ₹101 (up from ₹67.22 in FY 2023). Revenue: ₹14.9b (up 6.2% from FY 2023). Net income: ₹1.23b (up 51% from FY 2023). Profit margin: 8.2% (up from 5.8% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Tillkännagivande • May 22
Kingfa Science & Technology (India) Limited to Report Q4, 2024 Results on May 28, 2024 Kingfa Science & Technology (India) Limited announced that they will report Q4, 2024 results on May 28, 2024 Tillkännagivande • May 16
Kingfa Science & Technology (India) Limited Announces Cessation of N. Subramanian as an Independent Director Kingfa Science & Technology (India) Limited informed that the Board of Directors in their meeting held on May 15, 2024, has considered and approved the following: Mr. N. Subramanian has completed his second term of 5 (Five) years as an Independent Director and consequently ceased to be a Director of the Company with effect from the close of business hours on May 15, 2024. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,813, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 202% over the past three years. Reported Earnings • Feb 07
Third quarter 2024 earnings released: EPS: ₹20.09 (vs ₹16.71 in 3Q 2023) Third quarter 2024 results: EPS: ₹20.09 (up from ₹16.71 in 3Q 2023). Revenue: ₹3.95b (up 16% from 3Q 2023). Net income: ₹243.3m (up 20% from 3Q 2023). Profit margin: 6.2% (up from 6.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 49% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jan 25
Kingfa Science & Technology (India) Limited to Report Q3, 2024 Results on Feb 06, 2024 Kingfa Science & Technology (India) Limited announced that they will report Q3, 2024 results on Feb 06, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: EPS: ₹24.44 (vs ₹18.24 in 2Q 2023) Second quarter 2024 results: EPS: ₹24.44 (up from ₹18.24 in 2Q 2023). Revenue: ₹3.51b (flat on 2Q 2023). Net income: ₹296.0m (up 34% from 2Q 2023). Profit margin: 8.4% (up from 6.3% in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 60% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Oct 28
Kingfa Science & Technology (India) Limited to Report Q2, 2024 Results on Nov 07, 2023 Kingfa Science & Technology (India) Limited announced that they will report Q2, 2024 results on Nov 07, 2023 New Risk • Oct 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • Aug 31
Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 26, 2023 Kingfa Science & Technology (India) Limited, Annual General Meeting, Sep 26, 2023, at 11:30 Indian Standard Time. Agenda: To consider Adoption of Audited Financial Statements of the Company for the Financial Year ended March 31, 2023; to consider re-appointment of Mr. Wu Xiaohui; to consider; to consider Approval for Payment of Commission to Independent Directors; to consider ratification of Remuneration to Cost Auditor and to consider such other matters. Reported Earnings • Aug 06
First quarter 2024 earnings released: EPS: ₹28.93 (vs ₹2.04 in 1Q 2023) First quarter 2024 results: EPS: ₹28.93 (up from ₹2.04 in 1Q 2023). Revenue: ₹3.41b (down 1.4% from 1Q 2023). Net income: ₹350.4m (up ₹325.6m from 1Q 2023). Profit margin: 10% (up from 0.7% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jul 29
Kingfa Science & Technology (India) Limited to Report Q1, 2024 Results on Aug 05, 2023 Kingfa Science & Technology (India) Limited announced that they will report Q1, 2024 results on Aug 05, 2023 Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹67.22 (vs ₹25.29 in FY 2022) Full year 2023 results: EPS: ₹67.22 (up from ₹25.29 in FY 2022). Revenue: ₹14.1b (up 34% from FY 2022). Net income: ₹814.1m (up 166% from FY 2022). Profit margin: 5.8% (up from 2.9% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2,042, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 383% over the past three years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,539, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 282% over the past three years. Reported Earnings • Feb 17
Third quarter 2023 earnings released: EPS: ₹16.71 (vs ₹6.16 in 3Q 2022) Third quarter 2023 results: EPS: ₹16.71 (up from ₹6.16 in 3Q 2022). Revenue: ₹3.39b (up 32% from 3Q 2022). Net income: ₹202.3m (up 171% from 3Q 2022). Profit margin: 6.0% (up from 2.9% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 27% per year. Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,440, the stock trades at a trailing P/E ratio of 48x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 144% over the past three years. Tillkännagivande • Feb 03
Kingfa Science & Technology (India) Limited to Report Q3, 2023 Results on Feb 14, 2023 Kingfa Science & Technology (India) Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹18.24 (vs ₹6.15 in 2Q 2022) Second quarter 2023 results: EPS: ₹18.24 (up from ₹6.15 in 2Q 2022). Revenue: ₹3.51b (up 33% from 2Q 2022). Net income: ₹220.9m (up 197% from 2Q 2022). Profit margin: 6.3% (up from 2.8% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Executive Director Doraiswami Balaji was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Second quarter 2023 earnings released: EPS: ₹18.24 (vs ₹6.15 in 2Q 2022) Second quarter 2023 results: EPS: ₹18.24 (up from ₹6.15 in 2Q 2022). Revenue: ₹3.52b (up 33% from 2Q 2022). Net income: ₹220.9m (up 197% from 2Q 2022). Profit margin: 6.3% (up from 2.8% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₹1,224, the stock trades at a trailing P/E ratio of 69.8x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 82% over the past three years. Valuation Update With 7 Day Price Move • Aug 26
Investor sentiment improved over the past week After last week's 22% share price gain to ₹1,231, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 101% over the past three years. Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: ₹2.04 (vs ₹9.68 in 1Q 2022) First quarter 2023 results: EPS: ₹2.04 (down from ₹9.68 in 1Q 2022). Revenue: ₹3.46b (up 56% from 1Q 2022). Net income: ₹24.7m (down 79% from 1Q 2022). Profit margin: 0.7% (down from 5.3% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improved over the past week After last week's 18% share price gain to ₹904, the stock trades at a trailing P/E ratio of 33.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 35% over the past three years. Reported Earnings • May 29
Full year 2022 earnings released: EPS: ₹25.29 (vs ₹4.39 in FY 2021) Full year 2022 results: EPS: ₹25.29 (up from ₹4.39 in FY 2021). Revenue: ₹10.5b (up 67% from FY 2021). Net income: ₹306.3m (up 476% from FY 2021). Profit margin: 2.9% (up from 0.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹937, the stock trades at a trailing P/E ratio of 40.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 56% over the past three years. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Executive Director Doraiswami Balaji was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹6.16 (up from ₹1.36 in 3Q 2021). Revenue: ₹2.56b (up 32% from 3Q 2021). Net income: ₹74.6m (up 354% from 3Q 2021). Profit margin: 2.9% (up from 0.8% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 30% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 24% share price gain to ₹1,348, the stock trades at a trailing P/E ratio of 73x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 69% over the past three years. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment improved over the past week After last week's 17% share price gain to ₹1,086, the stock trades at a trailing P/E ratio of 55.9x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 51% over the past three years. Board Change • Nov 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Executive Director Doraiswami Balaji was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 01
Second quarter 2022 earnings released: EPS ₹6.15 (vs ₹2.73 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹2.65b (up 58% from 2Q 2021). Net income: ₹74.5m (up 126% from 2Q 2021). Profit margin: 2.8% (up from 2.0% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 05
New 90-day high: ₹718 The company is up 35% from its price of ₹533 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. Reported Earnings • Feb 11
Third quarter 2021 earnings released: EPS ₹1.36 (vs ₹6.29 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹1.96b (up 3.8% from 3Q 2020). Net income: ₹16.5m (down 78% from 3Q 2020). Profit margin: 0.8% (down from 4.0% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 16% per year. Is New 90 Day High Low • Jan 19
New 90-day high: ₹692 The company is up 30% from its price of ₹532 on 21 October 2020. The Indian market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₹636 The company is up 27% from its price of ₹500 on 06 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment improved over the past week After last week's 15% share price gain to ₹619, the stock is trading at a trailing P/E ratio of 68x, up from the previous P/E ratio of 59.1x. This compares to an average P/E of 18x in the Chemicals industry in India. Total return to shareholders over the past three years is a loss of 25%.